MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare MaxCyte to similar businesses based on the strength of its dividends, valuation, profitability, institutional ownership, earnings, analyst recommendations and risk.
Valuation & Earnings
This table compares MaxCyte and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MaxCyte||$33.89 million||-$19.08 million||-25.88|
|MaxCyte Competitors||$2.80 billion||$101.15 million||17.11|
This is a breakdown of current ratings for MaxCyte and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 42.61%. Given MaxCyte’s competitors higher probable upside, analysts clearly believe MaxCyte has less favorable growth aspects than its competitors.
This table compares MaxCyte and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
65.9% of MaxCyte shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 5.4% of MaxCyte shares are owned by company insiders. Comparatively, 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
MaxCyte competitors beat MaxCyte on 6 of the 11 factors compared.
MaxCyte Company Profile (Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.